PT-141 and Bremelanotide Research Guide: Melanocortin Evidence and Product Boundaries
PT-141 and Bremelanotide Research Guide: Melanocortin Evidence and Product Boundaries
A primary-source guide to bremelanotide human trials, melanocortin signaling, blood-pressure research, and the difference between a studied drug product and a research vial.
Human evidence exists, but product equivalence still matters
PT-141 is the development code associated with bremelanotide, a cyclic melanocortin-receptor agonist. Human research includes small early crossover studies, controlled dose-finding work, ambulatory blood-pressure analysis, and two large phase 3 trials in a defined premenopausal population.
This is a stronger human evidence base than many research peptides, but it is indication-, formulation-, and population-specific. Clinical findings from a regulated drug-development program do not establish that a laboratory-labeled powder is equivalent in identity, purity, formulation, sterility, or intended use.
Commercial research copy should explain the science and the boundary. It should not provide dosing, administration, treatment advice, or promises about sexual function.
What researchers are trying to understand
Are PT-141 and bremelanotide the same molecule?
PT-141 is the development name associated with bremelanotide. A vendor still must establish the identity of its own lot; name matching alone is not enough.
What does bremelanotide target?
It is studied as a melanocortin-receptor agonist, with central MC4R-related signaling important to the development rationale. It is not a PDE5 inhibitor.
Can drug-trial findings be used to market a research vial?
No. Trial evidence belongs to defined investigational or approved formulations and populations, not automatically to a separate research-market product.
Notable studies, in plain English
The studies below are separated by model and design so that early laboratory signals are not confused with evidence from people.
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist
- Model
- Human
- Design
- Double-blind, placebo-controlled crossover study in 18 premenopausal women with sexual-arousal disorder.
What the paper reported: The study reported differences in selected subjective response measures, while a physiologic vaginal-pulse-amplitude measure did not significantly differ.
Important limit: Very small, short-term study with mixed endpoints and a narrow clinical population.
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial
- Model
- Human
- Design
- Randomized, placebo-controlled, double-blind dose-finding trial in premenopausal women.
What the paper reported: The trial reported changes in prespecified event, function, and distress scales in selected study groups.
Important limit: Developer-sponsored, indication-specific results do not generalize to other populations or products.
Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide
- Model
- Human
- Design
- Ambulatory blood-pressure analysis within the bremelanotide development program.
What the paper reported: The study characterized transient blood-pressure and heart-rate effects under controlled conditions.
Important limit: Safety monitoring in a development program does not establish safety of unverified research products or unsupervised use.
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
- Model
- Human
- Design
- Two multicenter, randomized, double-blind, placebo-controlled phase 3 trials in 1,267 premenopausal women.
What the paper reported: The trials reported changes in co-primary desire and distress measures and characterized adverse events over the controlled period.
Important limit: The evidence is limited to a defined diagnosis, population, formulation, and clinical protocol; it does not validate research vials.
What the evidence does—and does not—establish
Although controlled human evidence exists, it addresses a regulated development product in a narrowly defined population. It should not be generalized to men, other diagnoses, wellness goals, or laboratory products.
Subjective scales, physiologic measures, blood pressure, and adverse events answer different questions. A balanced guide should show mixed or null findings and safety observations beside efficacy endpoints.
A research-vial listing must remain separate from medical use. It should not borrow approved-product positioning, instructions, or outcome language.
- PT-141 is the development name associated with bremelanotide.
- Controlled human trials exist in a defined premenopausal population.
- Blood-pressure effects were studied and should not be omitted.
- Clinical formulation evidence does not validate a research vial.
- No dosing or human-use directions belong on the research page.
Where to buy PT-141 / Bremelanotide for laboratory research in the USA
A research-only listing should disclose the cyclic peptide identity, counterion or salt form, theoretical and observed mass, purity method, labeled quantity, lot number, and intended laboratory status. It must not resemble a prescription-drug instruction page.
The lot-specific COA, underlying chromatogram, test date, storage documentation, shipping origin, and support contact should be readily available. Literature links can explain bremelanotide research, but they cannot replace identity, impurity, or sterility evidence for the listed lot.
Searches such as “where to buy PT-141,” “buy PT-141 USA,” and “USA peptides” should be treated as laboratory-sourcing questions. Compare U.S. research suppliers by lot traceability, identity testing, quantitative-content information, analytical methods, and stated research-use restrictions—not by implied human outcomes.
PT-141 / Bremelanotide research FAQ
Is PT-141 the same as bremelanotide?
PT-141 is the development code associated with bremelanotide, but a seller must still prove the identity of its own material.
Is bremelanotide a PDE5 inhibitor?
No. It is a melanocortin-receptor agonist with a different research mechanism.
Do phase 3 results validate a research peptide vial?
No. Those results concern a defined clinical formulation, manufacturing system, population, and protocol.
Why mention blood pressure in an evidence guide?
Because the development literature specifically evaluated cardiovascular changes. Balanced evidence copy should not omit safety-related endpoints.
What should a PT-141 COA show?
It should connect a specific lot to peptide identity, observed mass, chromatographic purity, test date, and the responsible method or laboratory.
Primary references
References link to the original journal record or publisher page. Inclusion is not an endorsement of a product or a clinical conclusion.
- Diamond LE et al. Journal of Sexual Medicine. 2006;3:628-638. PMID 16839319. DOI 10.1111/j.1743-6109.2006.00268.x.
- Clayton AH et al. Women's Health. 2016;12:325-337. PMID 27181790. DOI 10.2217/whe-2016-0018.
- Journal of Hypertension. 2017. PMID 27977473. DOI 10.1097/HJH.0000000000001221.
- Kingsberg SA et al. Obstetrics & Gynecology. 2019;134:899-908. PMID 31599840. DOI 10.1097/AOG.0000000000003500.